Natixis’s GoodRx Holdings GDRX Stock Holding History

Natixis’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,614	Closed	-$67.8K	–	1124
2025 Q2	$67.8K	Hold	13,614	–	–	﹤0.01%	862
2025 Q1	$59.7K	Buy	+13,614	New	+$63.9K	﹤0.01%	819

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Natixis's GDRX Position: Q3 2025 in Review

Natixis sold out of GoodRx Holdings (GDRX) in Q3 2025, closing a stake of 13,614 shares — an estimated $67.8K sold.

Natixis first reported a position in GDRX in Q1 2025 and held it in 2 quarters. The position peaked at $67.8K in Q2 2025. 161 funds tracked by Wall St. Rank hold GDRX as of Q3 2025.

Natixis reported no remaining GoodRx Holdings position as of Q3 2025 after selling out during the quarter.
Natixis sold 13,614 GoodRx Holdings shares in Q3 2025, an estimated $67.8K.
Natixis first reported a position in GoodRx Holdings in Q1 2025 and held it in 2 quarters.
Natixis's GoodRx Holdings position peaked at $67.8K in Q2 2025.
161 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2025.

Based on Natixis's 13F filing for Q3 2025, filed 14 Nov 2025.